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Abstract 
Cancer is one of the most wide-spread diseases of modern times, with an estimated increase in the number 
of patients diagnosed worldwide, from 11.3 million in 2007 to 15.5 million in 2030 (www.who.int). In 
many cases, due to the delay in diagnosis and high increase of relapse, survival rates are low. Current 
therapies, including surgery, radiation and chemotherapy, have made significant progress, but they have 
many limitations and are far from ideal. Although immunotherapy has recently offered great promise as a 
new approach in cancer treatment, it is still very much in its infancy and more information on this approach 
is required before it can be widely applied. For these reasons effective, safe and patient-acceptable cancer 
therapy is still largely an unmet clinical need. Recent knowledge of the genetic basis of the disease opens 
up the potential for cancer gene therapeutics based on siRNA. However, the future of such gene-based 
therapeutics is dependent on achieving successful delivery. Extensive research is ongoing regarding the 
design and assessment of non-viral delivery technologies for siRNA to treat a wide range of cancers. 
Preliminary results on the first human Phase I trial for solid tumours, using a targeted non-viral vector, 
illustrate the enormous therapeutic benefits once the issue of delivery is resolved. In this review the genes 
regulating cancer will be discussed and potential therapeutic targets will be identified. The physiological 
and biochemical changes caused by tumours, and the potential to exploit this knowledge to produce 
bio-responsive ‘smart’ delivery systems, will be evaluated. This review will also provide a critical and 
comprehensive overview of the different non-viral formulation strategies under investigation for siRNA 
delivery, with particular emphasis on those designed to exploit the physiological environment of the 
disease site. In addition, a section of the review will be dedicated to pre-clinical animal models used to 
evaluate the stability, safety and efficacy of the delivery systems. 
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1. Introduction 
Cancer is a major public health problem in many parts of the world, and a total of 1,529,560 new cases and 
569,490 deaths from
 
cancer are projected to occur in the United States in 2010 (Jemal et al., 2010). 
Surgical therapy can sometimes cause a tumour-related inflammatory response due to trauma, necrosis, and 
tissue injury, resulting in neoangiogenesis, tumour progression and triggering of local immunosuppression 
(Grivennikov et al., 2010). Radiation and non-specific chemotherapy cause significant necrotic death of 
cancer cells, as well as damage to surrounding healthy tissues, which may induce significant morbidity and 
potentially fatal outcomes. Additionally, antitumour immunotherapy is only seen with certain drugs, as 
tumour promoting inflammation and antitumour immunity coexist at different points along the pathway of 
tumour development (Swann et al., 2008). With increasing reports on the molecular mechanisms of the 
RNAi pathway, the discovery of gene silencing by small interfering RNA (siRNA) has revolutionised this 
area and presents new opportunities for the successful achievement of gene-based therapies ([de 
Fougerolles et al., 2007] and [Baker, 2010a]). Increasing knowledge of the genetic basis of cancer has 
accelerated the application of siRNA as a new generation of cancer therapeutics (Masiero et al., 2007). 
However, the future of such gene-based therapeutics is dependent on the availability of safe, effective and 
stable delivery systems. To date, while many non-viral delivery vectors have shown potential in vitro, this 
has not always translated into comparative success in vivo ([Bumcrot et al., 2006] and [Baker, 2010b]). In 
spite of the significant challenges, many clinical trials have been initiated with siRNA. In several of these 
trials siRNA is given by local administration, however, for the effective treatment of metastatic cancer, 
systemic delivery will be essential. Recent developments in nanotechnology raise exciting opportunities for 
the design and formulation of targeted non-viral delivery constructs for siRNA capable of overcoming the 
barriers to in vivo delivery ([Whitehead et al., 2009] and [Guo et al., 2010]). This review will provide a 
critical and comprehensive overview of the different formulation strategies under investigation, with 
particular emphasis on those designed to exploit the physiological environment of the disease site.  
 
2. Therapeutic Potential of siRNA 
2.1 RNAi mechanism 
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The term gene transfer has traditionally been used to describe the delivery of DNA containing a coded 
sequence for a therapeutic protein. In addition to the delivery of plasmid DNA (pDNA) into the nucleus of 
target cells, gene therapy also includes nucleic acid delivery where silencing of endogenous gene 
expression using RNAi and/or antisense oligonucleotides (ASOs) in the cytoplasma is desired. In 
comparison to ASO-based therapies, the therapeutic application of the RNAi-based approach is a recent 
discovery. It has a number of advantages over ASO, including improved stability in vivo and longer 
silencing activity (Fattal and Barratt, 2009).  
RNAi is a biological mechanism by which double-stranded RNA (dsRNA) inhibits gene expression in a 
sequence dependent manner through degradation and/or blockage of the corresponding mRNA. Fire et al. 
in 1998 (Fire et al., 1998) described the use and potency of dsRNA, first discovered in plants (van der 
Vlugt et al., 1992), to modulate gene expression in the roundworm Caenorhabditis elegans. The first 
demonstration that siRNA duplexes could be used in mammalian cells to block gene expression (Elbashir 
et al., 2001) provided a new tool for evaluating gene function in mammalian cells and offered the potential 
to develop gene-specific therapeutics. RNAi machinery is composed of small RNAs that mainly comprise 
microRNA (miRNA) and siRNA. miRNA induces translational suppression and transcript deprivation for 
imperfectly complementary mRNA sequences, whereas siRNA mediates gene knockdown via 
sequence-specific cleavage of perfectly matching complementarities (Jackson and Linsley, 2010).  
siRNA-triggered gene silencing may be achieved by two basic strategies: 1) where viral or plasmid-based 
vectors enter the nucleus and are transcribed to produce short hairpin RNAs which are transported to the 
cytoplasm and processed into siRNAs by Dicer (Lares et al., 2010), and 2) the introduction of synthetic 
siRNA (21-23 nucleotides) into the cytoplasm, for direct processing via the RNA-induced silencing 
complex (RISC), this conveniently bypasses the Dicer mechanism (Jackson and Linsley, 2010). The 
shRNA-mediated approach has the potential to be stably introduced to produce siRNAs, however, 
vector-based shRNA systems mainly rely on delivery via viral vectors, which have many potenital side 
effects, such as immunotoxicity and mutagenesis (Guo et al., 2010). In contrast, repeat administration of 
synthetic siRNAs has been reported to achieve long-term silencing of target genes without disrupting the 
endogenous microRNA pathways (John et al., 2007). Currently, several synthetic siRNAs are undergoing 
clinical trials for macular degeneration, kidney injury, respiratory infection, and cancer ([Whitehead et al., 
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2009], [Castanotto and Rossi, 2009] and [Guo et al., 2010]). The main focus of this review is on non-viral 
formulation strategies for synthetic siRNA delivery. 
2.2 Genetic regulation of cancer – identifying targets for gene silencing as a therapeutic strategy 
The biology of carcinogenesis is complex, involving a network of signal-tranducing pathways (Campbell et 
al., 2010). Knowledge of the genetic basis of the disease facilitates identification of the key genes which 
initiate and regulate disease progression. Specific knockdown of these genes should alleviate the disease. 
However, as several oncogenes and oncosuppressors influence the development of cancer to varying 
degrees it is challenging to identify one key gene and it may be necessary to silence multiple genes 
simultaneously. Indeed the ability and availability of appropriately designed siRNAs to down-regulate 
almost any gene in the cell can be a significant advantage over conventional chemotherapies which tend to 
utilise a more limited range of targets (Whitehead et al., 2009). Several RNAi based approaches for cancer 
therapy have been studied, including silencing of genes involved in oncogenesis pathways, apoptosis, cell 
cycle regulation, cell senescence, tumour-host interaction, and resistance to conventional therapies. The 
genes involved in these approaches have been described elsewhere (Masiero et al., 2007) and while such 
detail is beyond the scope of this review, selected recent examples will be discussed (Figure 1). 
Figure 1. 
Oncogenesis pathway: The protein tyrosine kinases are important molecules associated with intracellular 
signal transduction, and their kinase activity can be improved or induced by several genetic alterations such 
as chromosomal translocations, gain-of-function mutations and gene amplifications, resulting in oncogenic 
transformation. EphB4 (a transmembrane receptor tyrosine kinase) is overexpressed in ovarian cancer and 
is predictive of poor clinical outcome. Silencing of this gene using a lipid-mediated siRNA system 
remarkably increased tumour cell apoptosis and reduced migration (Spannuth et al., 2010). Combination 
with docetaxel led to synergistic suppression of tumour growth in two ovarian carcinoma animal models 
(Spannuth et al., 2010), implying that EphB4 is a valuable therapeutic target in ovarian cancer. 
Apoptosis: Several anti-apoptotic factors expressed in cancer have conferred resistance to different 
apoptotic triggers, including oxidative stress, deprivation of growth factors, and DNA damage. Blockage of 
cell death by these factors can lead to survival under abnormal growth stimuli, and, to chemio- and 
radio-resistance. The role of anti-apoptotic proteins, a common mechanism responsible for chemoresistance 
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in chondrosarcomas, has recently been investigated (Kim et al., 2009). In this study, siRNA knockdown as 
well as pharmacologic inhibitors of survival proteins (Bcl-2, Bcl-xL and XIAP) induced apoptosis and led 
to enhanced chemosensitivity of doxorubicin, suggesting a significant function of anti-apoptotic proteins in 
the resistance of chemotherapeutics. 
Cell cycle regulation: Knockdown of certain genes involved in cell cycle control can arrest cell division 
and enhance apoptosis. For example, upregulation of anterior-gradient 2 (AGR2, an estrogen-responsive 
secreted protein related to poor prognosis) has been observed in a number of cancers, especially breast 
cancer (Vanderlaag et al., 2010). In estrogen-receptor-α (ER)-positive breast cancer cell lines, silencing of 
AGR2 by siRNA resulted in downregulation of ER and cyclin D1 (a mitogenic sensor that responds to 
oncogenes and various growth factors), indicating the potential of anti-AGR2 therapy in ER-postive breast 
cancers (Vanderlaag et al., 2010). 
Cell senescence: Cells are able to divide a finite number of times, initiating senescence only when 
telomeres reach a critically short length; in contrast, most cancer cells express telomerases with maintained 
length (Masiero et al., 2007). The effects of human telomerase reverse transcriptase (hTERT) on 
anti-apoptosis of Capan-2 human pancreatic cancer cells have recently been described (Zhong et al., 2010). 
In this study, cell growth was remarkably suppressed following hTERT-siRNA transfection, and apoptotic 
cells were significantly increased, accompanied with downregulation of Bcl-2 and cyclooxygenase 
(COX)-2, consistent with an increase of cells in the G0/G1 phase and a decrease in the S phase and G2/M 
phase. 
Angiogenesis: Inhibition of tumour vasculature development, called angiogenesis, by suppression of 
angiogenesis activators is an effective strategy to treat cancer. The vascular endothelial growth factor 
(VEGF), one of the most important angiogenesis oncogenes, has been substantially investigated as an 
anti-angiogenesis target. Following intratumoural administration of VEGF-C-specific siRNA complexed 
calcium carbonate (CaCO3) nanoparticles into mice grafted subcutaneously with gastric tumour, the data 
indicated dramatic suppression of tumour lymphangiogenesis, tumour growth and regional lymph-node 
metastasis, accompanied with significant downregulation of VEGF-C mRNA level, without showing 
cytoxicity (He et al., 2008). 
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Invasion and metastasis: There are many factors in tumourigenesis which facilitate tumour progression 
and propagation, including new blood vessel formation, extra-cellular matrix (ECM) remodeling, improved 
motility of cancer cells and immune evasion ([Masiero et al., 2007] and [Campbell et al., 2010]). The 
secreted protein acidic and rich in cysteine (SPARC), a secreted glycoprotein, is well documented to play a 
key role in enhancing the motility of invasive tumour cells. Downregulation of SPARC expression 
inhibited cell migration and invasion following intracerebral injection of a lipid-formulated SPARC siRNA 
in nude mice grafted with glioma cells (Seno et al., 2009). 
Resistance to conventional therapies: P-glycoprotein, a multi-specific drug efflux transporter, impedes the 
permeability of anti-cancer drugs through physiological barriers causing limited pharmacological activity. 
For example, improved therapeutic efficacy of paclitaxel was described in a tumour-bearing mouse model 
when co-delivering siRNA against the MDR1 gene that encodes P-gp. (Patil et al., 2010). Although 
adjuvant chemotherapy for breast cancer after surgury has significantly reduced metastatic relapse, a 
considerable number of women suffer recurrent cancer due to drug resistance. Recently, it was 
demonstrated that overexpression of YWHAZ (an anti-apoptotic gene) and LAPTM4B (a lysosomal gene) 
was associated with poor tumour response to anthracycline treatment in a neoadjuvant chemotherapy trial. 
Down-regulation of either of the two genes using a lipid-mediated siRNA vector enhanced distribution of 
doxorubicin into the nucleus, suggesting a synergistic effect when combined with chemotherapy (Li et al., 
2010a).  
In addition, simultaneous silencing of these abovementioned oncogenes by a mixture of siRNAs has 
presented a promising strategy for cancer gene therapy ([Song et al., 2005], [Li et al., 2008a] and [Chen et 
al., 2010a]).  
 
3. Challenges for development of siRNA therapeutics 
The development of siRNA-based therapeutics promises great potential for the treatment of major diseases 
such as cancer. However, in order to achieve these goals, significant challenges specifically related to the 
nature of siRNA including off-target effects, immunogenicity, stability and effective delivery, must be 
overcome. 
3.1 Sequence-dependent off-target effects 
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Jackson et al. 2003 first revealed the miRNA-like off-target effects of siRNAs, suggesting that this 
off-target activity was induced in mRNAs only when 7 or 8 nucleotides in 3’ UTR were matching with the 
5’ end of siRNAs (Jackson et al., 2003). This off-target effect was reduced when base mismatches occurred 
on the 5’ end of the siRNA guide strand, but the gene off-targeting was restored on introduction of a new 
set of transcripts with 3’ UTRs that were complementary to the mismatched guide strand (Jackson et al. 
2006a).  
Since the seed section of the 5’-phosphate group of the siRNA-guide strand is implicated in off-target 
knockdown, it seems to be important to ensure siRNA is fully homologous to the intended mRNA but not 
complementary to any sequences in the 3’ UTR of non-targeted genes ([Khvorova et al., 2003] and 
[Reynolds et al., 2004]). This has contributed to the advances of numerous design algorithms that improve 
the selection of highly functional siRNA duplexes ([Huesken et al., 2005], [Jagla et al., 2005] and [Naito et 
al., 2009]). Furthermore, it has recently been reported that the ability of siRNA to induce miRNA-like 
off-target activity is strongly associated with the melting temperature (Tm) of the seed duplex formed 
between seed and target (Ui-Tei et al., 2008). In this study, it was suggested that a Tm of 21.5 °C may 
function as the benchmark, which distinguishes the almost off-target-negative seed sequences from the 
off-target-positive ones, resulting in minimum seed-dependent off-target knockdown (Ui-Tei et al., 2008). 
 
Chemical modification is another approach to decrease miRNA-like off-target effects. For example, it has 
been shown that 2’-O-methyl modification in the siRNA antisense strand significantly reduced the 
off-target effects, but demonstrated complete silencing of perfectly matched targets (Jackson et al., 2006b). 
Furthermore, 5’-O-methylation can be utilised to nullify the formation of siRNA-sense-RISC and enhance 
the incorporation of siRNA-antisense-RISC (Chen et al., 2008). In addition, it has been reported that 
siRNA-induced toxic phenotypes can be promoted by a preponderance of specific motifs such as –UGGC- 
and other –AU- rich pentamers including –AUUUG, GUUUU, AUUUU, CUUUU, UUUUU, GUUUG- 
(Jackson and Linsley, 2010),
 
thus application of such motifs should be minimised if possible.  
3.2 Immune stimulation off-target effects 
Initial studies demonstrated that the introduction of dsRNA longer than 30 bases into mammalian cells can 
trigger the recognition of the serine/threonine protein kinase receptor (PKR-a cytosolic RNA-binding 
receptor), leading to considerable toxicities associated with excessive cytokine release and related 
inflammatory syndromes in humans (Robbins et al., 2009). However, recent reports indicate that synthetic 
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siRNAs can also induce undesirable side effects in vitro and in vivo ([Judge and MacLachlan, 2008] and 
[Robbins et al., 2009]). Indeed, systemic administration of synthetic siRNAs can activate high levels of 
inflammatory cytokines such as tumour necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and interferon 
(IFN, in particular IFN-α). This immune stimulation is primarily mediated by immune cells, normally via a 
Toll-like receptor (TLR) pathway. Three TLR receptors, namely TLR7, TLR8 and TLR3, are mainly 
involved in siRNA-based immune stimulation (Robbins et al., 2009). Judge et al. first presented GU-rich 
sequences as being highly immunostimulatory and recognised that 5’-UGUGU-3’ in certain siRNAs 
conferred this effect (Judge et al., 2005). In addition to 5’-UGUGU-3’, it was shown that the presence of a 
ribose sugar backbone is essential for TLR7 recognition (Diebold et al., 2006). Endothelial cell surface 
TLR3 is also triggered by exogenous siRNA in vivo, leading to the production of cytokines such as IFN 
and IL-12 (Kleinman et al., 2008).  
Furthermore, mammalian cells have also evolved numerous TLR-independent mechanisms that detect 
foreign RNAs in the cytoplasm and are active against viral infection and replication (Robbins et al., 2009). 
Other non-TLR-sensitive responses to siRNA are frequently activated by the cytosolic RNA-binding 
proteins like RIG1 proteins (RIG1, is a cytoplasmic RNA helicase, which binds either single-stranded or 
double-stranded RNA containing uncapped 5’-triphosphates) ([Hornung et al., 2006] and [Pichlmair et al., 
2006]). The immune stimulatory effects induced by TLR receptors and/or cytoplasmic RNA receptors may 
result in the toxic consequences that significantly obstruct loss-of-function investigations and therapeutic 
applications. Resulting from the many literature reports describing immune stimulatory off-target effects, 
siRNAs have been substantially improved in many ways including avoiding high uridine content, and the 
introduction of certain chemical modifications ([Judge and MacLachlan, 2008] and [Robbins et al., 2009]). 
3.3 Stability 
It has been reported that naked siRNA are degraded in human plasma with a half-life of minutes (de 
Fougerolles et al., 2007). Increasing efforts have been focused on enhancing siRNA stability by a variety of 
chemical modifications without compromising the silencing ability per se ([Bumcrot et al., 2006] and [de 
Fougerolles et al., 2007]). For example, stability against nuclease degradation can be achieved via the 
introduction of a phosphorothioate (P=S) backbone linkage at the 3’ end for exonuclease resistance, and, a 
2’ modifications (2’-O-methyl and 2’-fluoro) for endonuclease resistance (Bramsen et al., 2009). Other 
improved oligonucleotide chemistries have also been established, such as locked nucleic acids (LNAs) and 
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hexitol nucleic acids (HNAs) (Gao et al., 2009). Moreover, it is interesting to note that incorporation of 
unlocked nucleic acid (UNA) into siRNAs has been recently reported to significantly enhance the 
bioactivity of siRNAs in vitro and in vivo (Laursen et al., 2010). With recent progresses in nucleotide 
chemistry, the modifications described in this section may stabilise siRNAs against nuclease degradation, 
as compared to unmodified siRNAs when formulated into various carrier systems for in vivo delivery 
(Whitehead et al., 2009).  
3.4 Delivery of siRNA 
The success of siRNA technology has been widely reported using in vitro cell models, however, while 
progress using in vivo models has been rapid over the last decade, the production of a robust safe and 
efficient gene-based medicine has been limited by delivery ([Whitehead et al., 2009] and [Guo et al., 
2010]). Barriers to in vivo delivery occur at many levels and will be influenced by the route of 
administration (Howard, 2009), and the physiological and biochemical milieu of the disease environment. 
Non-parenteral administration, such as oral or pulmonary, is desirable due to the non-invasive nature and 
the high degree of patient acceptance. However, following oral administration the hostile environment of 
the gut lumen including extremes of pH and enzymes may pose significant barriers to stability (O’Neill et 
al., 2011). In the case of pulmonary administration, barriers to absorption include the presence of enzymes, 
mucus and poor membrane permeability. Consequently, application of siRNA directly to the target tissue 
(localised administration including intraocular, intracranial, intratumoural, intranasal and topical delivery), 
or, parenteral delivery (i.e. intravenous injection with circulation throughout the blood to the target organ 
or tissue), are to date most frequently used. While local delivery facilitates a reduction in dose and 
site-specificity, it is limited by the accessibility of the target organ/tumour (Whitehead et al., 2009). In 
contrast, although intravenous delivery of siRNAs enables treatment of metastasic cancers, it also has 
limitations including interaction with plasma proteins, particle aggregation, and opsonisation (Phillips et al., 
2010). In summary, barriers to in vivo delivery must not be underestimated. To overcome the barriers a 
holistic approach needs to be taken incorporating consideration of the physicochemical properties of both 
siRNA and the delivery construct, the choice of the vector material and the physiological environment of 
the disease site. These factors will be discussed in the following sections.  
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4. Physiological and physicochemical challenges and opportunities for siRNA delivery in cancer 
therapy  
In vivo barriers to siRNA delivery include enzymatic degradation, short half-life and poor cellular uptake. 
These barriers can be alleviated via formulation in a stable, efficient, non-toxic delivery system, resulting 
in an improved pharmacokinetic profile for siRNA. In addition, in order to maximise delivery for a 
particular disease, such as cancer, it is essential to have a clear understanding of the environment at the 
disease site, which can then be exploited to design bioresponsive ‘smart’ delivery systems with enhanced 
specificity and superior therapeutic efficacy. 
4.1 Pharmacokinetics, tissue distribution and intracellular uptake of siRNA 
Non-formulated siRNA has an average size below 10nm and is subject to high renal clearance, short 
half-life (~0.3 h) and consequently limited duration of therapeutic activity (Figure 2) ([Bumcrot et al., 
2006], [de Fougerolles et al., 2007] and [Li et al., 2008c]). In order to increase the size, siRNA can be 
converted into longer lengths (Lee et al., 2010),
 
or chemically linked (i.e. by disulfide bonds and 
streptavadin/biotin) to other nucleic acids, proteins and poly(ethylene glycol) (PEG) (Jung et al., 2010). 
Another approach, displaying both improved particle size and enhanced siRNA stability in the extracellular 
environment, involves the application of non-viral vectors that are able to associate with siRNA to form 
complexes. In this way, delivery using non-viral vectors has the potential to improve the pharmacokinetics, 
pharmacodynamics, biodistribution and toxicological profile of siRNA ([de Fougerolles et al., 2007] and 
[Kim and Rossi, 2007]).  
Figure 2. 
The particle size of the complex has a critical impact on the ability of the complex to overcome delivery 
barriers in cancer therapy. Nanoparticles smaller than the renal filtration cut-off of 50 kDa or 5-6 nm are 
rapidly removed from the bloodstream and excreted (Choi et al., 2007). Particles less than 100nm in 
diameter are known to have higher accumulation levels in Kupffer cells in the liver; whereas, particles 
above 100nm are recognised and removed by the mononuclear phagocytic system (MPS, also known as the 
reticuloendothelial system (RES)), a phenomenon known as opsonisation, resulting in a short half-life 
(Figure 2) ([Owens and Peppas, 2006], [Alexis et al., 2008] and [Phillips et al., 2010]). One of the most 
widely characterised methods to avoid MPS uptake is the addition of a PEG moiety to form so called 
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‘stealth’ particles. PEG has since been used extensively to improve the pharmacokinetic properties of drugs, 
and as a component in gene delivery constructs (Phillips et al., 2010), albeit presenting unexpected 
immunostimulation in certain situations (Tagami et al., 2010). In addition, optimisation of particle size is 
essential to maximise the ‘enhanced penetration and retention’ (EPR) effect in tumour tissue, in which 
immature and porous vasculature provides access to circulating particles (reviewed later).  
Formulation of siRNA with positively charged vectors is utilised to neutralise the overall surface charge 
and thereby increase cellular internalisation. Although cationic complexes achieve high transfection in cell 
culture, in vivo the cationic charge causes major problems including interaction with negatively charged 
serum proteins, leading to clot-like accumulations that are either entrapped in the endothelial capillary bed 
or taken up by the RES (Figure 2) (Li and Szoka, 2007). When chemically grafted onto a cationic polymer, 
PEG can mask positively charged surfaces, thus stabilising the complexes against salt, protein and 
complement-induced inactivation (Pack et al., 2005). In addition, PEG allows for flexible attachment of 
targeting moieties that enable both cell specific targeting (discussed below), enhanced retention in the 
ECM of the tumour and increased cell uptake (Li and Huang, 2010).  
Figure 3 
Untargeted complexes bind electrostatically to the cell membrane and are internalised via adsorptive 
pinocytosis. In contrast, complexes with targeting ligands associate with specific cell-surface receptors and 
enter into cells by receptor-mediated endocytosis. Fluorescent/confocal microscopy and transmission 
electron microscopy are normally used to assess the complex entry and intracellular fate (Bhattacharyya et 
al., 2010). Alternatively, colocalisation between complexes and immunofluorescently stained proteins that 
are specific to certain endocytic compartments/pathways (i.e. caveolin 1, transferrin receptor) can also be 
investigated (Walsh et al., 2006). Following cellular uptake, these cargos often become entrapped inside 
the endosomes (Figure 3) (Dominska and Dykxhoorn, 2010). Complexes are considered to be mainly 
transported to late endosomes in which the pH quickly drops to ~5-6. Subsequently, they can be delivered 
into lysosomes, in which the pH further decreases to ~4.5, and where there are a variety of degradative 
enzymes (Dominska and Dykxhoorn, 2010). Only siRNA that escapes intact from the 
endosomes/lysosomes can arrive safely at the cytoplasm to enter into the RNAi pathway. Certain polymers, 
such as polyethyleneimine (PEI) and polyamidoamine (PAMAM), can escape from endosomes by what has 
been referred to as the ‘proton-sponge hypothesis’ where the H+ buffering capacity of polyamines results in 
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endosomal Cl
-
 accumulation during acidification, resulting in osmotic endosome swelling, bursting and 
subsequent particle escape (Mintzer and Simanek, 2009). Alternatively, cationic-lipid-based vectors result 
in membrane destabilisation when the anionic phospholipids of the membrane diffuse into the particle 
lipids (cationic) forming a charge neutral ion pair. siRNA then dissociates from the complex and is released 
into the cytoplasm (Li and Szoka, 2007). Furthermore, it has been recently reported that 
fusogenic/synthetic peptides (Hatakeyama et al., 2009) or pH-sensitive moieties ([Carmona et al., 2009] 
and [Akita et al., 2010])
 
can be attached to various polymers/lipids to assist endosomal escape. However, 
several studies have shown that multimerising peptides on the surface of the delivery vector cause 
immunogenicity following repeatedly intravenous administration ([Schroeder et al., 2009] and [Shi et al., 
2010]).  
A combinatorial delivery strategy for plasmid DNA has been described by Shi et al., 2010 to efficiently 
inhibit tumour growth in a human tumour microenvironment-pancreatic cancer mouse model. A small 
specific targeting ligand, less likely to elicit an immune response, was attached to the surface of a 
bilamellar invaginated vesicle (BIV). In addition, reversible masking to bypass nonspecific uptake in vivo 
was provided by a neutral, small molecular weight lipid (n-dodecyl-β-D-maltopyranoside), which was 
non-immunogenic and non-toxic and provided more efficient tissue distribution compared to PEG 
alternatives. This delivery strategy has potential for application to siRNA (Figure 2). 
Once released from the endosomal compartments, siRNA must subsequently dissociate from the complex 
in the cytoplasm to enter into the RNAi pathway (Figure 3). Several studies have found that 
decomplexation of plasmid DNA is improved by reducing the number of positive charges, shrinking 
conjugation of PEG, or decreasing the polymer molecular weight ([Pack et al., 2005] and [Howard, 2009]). 
Therefore, synthetic vectors must clearly be designed to incorporate a mechanism for nonspecific or 
environmentally responsive release of siRNA. 
4.2 Physiological and biochemical environment of the tumour 
As recently reviewed by Egeblad et al. (Egeblad et al., 2010), solid tumours are not random combinations 
of cells and extracellular matrix (ECM), but are structurally and functionally abnormal organs comprising 
multiple cells types and extracellular matrix components that develop a complex interaction with other 
tissues. Knowledge of the tumour microenvironment may present opportunities for the design of 
bioresponsive delivery systems (Figure 3). 
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Angiogenesis and EPR effect: As a tumour grows, it must recruit its own blood supply in order to fulfill 
the increasing metabolic requirements. In most tumours new blood vessels are formed via a process termed 
angiogenesis, whereby new blood vessels are formed from preexisting vasculature (Campbell et al., 2010). 
Unlike the tight blood vessels in normal tissues, angiogenic blood vessels in tumours have leaky 
vasculature gaps, and this can be exploited for enhanced penetration and accumulation of nanoparticles 
(NP) with an optimised size (diameter < 100~200nm). This phenomenon is known as the EPR effect 
(Figure 3) (Egeblad et al., 2010), and tumour retention can be improved by conjugation of a targeting 
ligand to the NP (Li and Huang, 2010). It is worth noting that targeting tumour lymphangiogenesis to 
inhibit lymphatic metastasis is complicated, as destruction of lymphatic vessels also increases the 
interstitial fluid pressure inside the tumour area, therefore leading to reduced delivery to cancer cells 
(Campbell et al., 2010). Recently, a PEGylated nanoparticle delivery system causing multistage 
accumulation into tumour tissues has been described (Wong et al., 2011). In this work, ~100 nm particles 
extravasate from leaky regions and then ‘shrink’ to ~10 nm nanoparticles when exposed to the tumour 
microenvironment, where matrix metalloproteinases (MMP) degrade the cores of the 100-nm gelatin 
particles releasing smaller nanoparticles from their surface. As a result, these smaller particles are more 
able to diffuse throughout the tumour interstital matrix (Wong et al., 2011). 
Reduced pH and extracellular enzymes: Tumours have specialised microenvironments or niches that offer 
distinct functions to support cancer cells. For example, physiological pH in the blood vessels is converted 
to a slightly acidic condition near the extracellular area of solid tumours. This low pH appears particularly 
able to trigger cancer cells with more invasive properties, and many cytotoxic drugs are impaired when 
exposed to this acidic environment (Egeblad et al., 2010).  
Many extracellular matrix components involved in tumour microenvironments support tumourigenesis, and 
can be used as prognostic factors for many human cancers. For example, MMP expressed in high levels in 
tumour cells and secreted into the ECM are associated with angiogenesis, invasion and metastasis of 
malignant cancers via its ability to degrade the ECM ([Davis and Senger, 2008] and [Campbell et al., 
2010]). In addition, carbonic anhydrase (CA, EC 4.2.1.1) isozyme, CA IX, is a transmembrane protein 
predominantly found in tumour cells and contributes highly to the extracellular acidification of solid 
hypoxic tumours (De Simone and Supuran, 2010). This enzyme plays a significant role in catalysing the 
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hydration of carbon dioxide to bicarbonate and protons at acidic pH environments, and is highly 
unresponsive to conventional chemo- and radiotherapy. 
The low pH and the presence of specific enzymes at the tumour site can be exploited for siRNA delivery. 
For example, PEGylated NPs are often utilised to prolong circulation and shield the surface charge of 
cationic complexes. However, following accumulation in the ECM, PEG deshielding is essential for 
cellular uptake. This can be achieved by conjugating the PEG chains via bioresponsive/biodegradable 
linkages which can be cleaved at the tumour site via the acidic pH or extracellular enzymes, thus exposing 
the cationic surface and enabling cellular uptake ([Hatakeyama et al., 2009], [Carmona et al., 2009] and 
[Akita et al., 2010]) (Figure 3). 
Specialised receptors: Tumour development is a complex process that involves interaction and 
communication between a variety of cellular compartments. For example, integrins (major ECM receptors) 
direct many of the influences of tumour-associated ECM on the cancer cells and inhibition of β-1 integrins 
impairs the malignant phenotype in culture and in vivo (Egeblad et al., 2010). Recently, cell specific 
targeted siRNA delivery systems have been developed to recognise receptors overexpressed in certain 
tumour tissues, including integrin (Peer et al., 2008), folic acid (FR) receptor (Lu et al., 2010), sigma 
receptor (Li et al., 2008b), insulin receptor (Xia et al., 2009), hyaluronic acid (HA) receptor (Park et al., 
2010) and transferrin receptor (TfR) (Davis et al., 2010). Using a high-throughput co-culture (primary 
human endothelial cells with human lung or pancreatic cancer cells) screening method Shi et al., 2010 
identified a small molecule (KB1023) that enhanced transfection efficiency of tumour-associated 
endothelial cells but not normal human endothelial cells or cancer cells. Following IV administration of 
this targeted complex to unidentified receptors using a plasmid encoding thrombospondin-1 tumours were 
eliminated completely after five injections (Shi et al., 2010). 
P-glycoprotein transporter: Efflux transporters, particularly P-glycoprotein (P-gp), have received 
enormous attention in both cancer and drug delivery research, due to their ability to restrict the efficacy of 
anti-cancer drugs. A variety of pharmaceutical excipients, including surfactants, polymers and lipids, have 
been utilised to suppress P-gp activity (Bansal et al., 2009). As mentioned previously (Section 2.2), 
knockdown of P-gp using siRNA has the potential to improve the therapeutic efficacy of certain 
anti-cancer drugs. Recently, this strategy was exploited using a guanidinium-lipid (DSAA) delivery vector 
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resulting in reduced drug resistance and enhanced DOX uptake in drug-resistant tumour cells (Chen et al., 
2010b). 
 
5. Pre-clinical animal models of cancer to evaluate the stability, toxicity and therapeutic efficacy of 
delivery constructs 
Potential to achieve successful in vivo delivery can only be assessed by using an appropriate experimental 
pre-clinical model. When initiating an in vivo study it is important to consider the species of animal, the 
type of tumour, the method of inducing the tumour, the location of the tumour, the target gene, the dosing 
schedule and the appropriate biological end point (i.e. local growth of the tumour, metastasis and survival 
of animals) ([Becker et al., 2010], and [Workman et al., 2010]). 
In terms of diseased animal models, tumours can be induced or they can occur spontaneously following 
repeated exposure to carcinogens or implantation of tumour cells. The spontaneous tumour models that 
normally arise following carcinogenic, radiation, viral or bacterial exposure mimic the clinical situation 
closely ([Workman et al., 2010] and [Westbrook et al., 2010]); however, significant hurdles impede the 
application of these model systems. In contrast, implantation of tumour cells subcutaneously into the flank 
of wild type or nude mice (xenograft) has been widely used as a simple model to study anticancer 
therapeutics usually by monitoring changes in tumour size ([Francia and Kerbel, 2010]). Alternatively, a 
more clinically-relevant system may be assessed using orthotopic and metastatic xenograft models that can 
reproduce the histology and metastatic pattern of the corresponding human disease at an advanced stage 
([Man et al., 2007], [Cruz-Munoz et al., 2008], [Becker et al., 2010] and [Workman et al., 2010]). In 
addition, genetically engineered mouse models (GEMMs) (also called transgenic mouse models) have been 
proposed as models to improve the performance of clinical trials for molecularly targeted therapies 
([Workman et al., 2010]). However, whether these models are superior to human tumour xenograft remains 
a subject of discussion and awaits further comparative analysis (Francia and Kerbel, 2010).  
The development of diseased models, as described above, is essential to the in vivo assessment of cancer 
therapeutics. A variety of biological endpoints have been utilised to quantify therapeutic efficacy and 
safety of siRNA delivery systems. In addition to monitoring tumour progression via tumour volume and 
survival times, gene silencing studies on endogenous oncogenes have been employed where the results are 
quantified via reverse transcriptase-polymerase chain reaction (RT-PCR) to measure mRNA expression 
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levels and western blot or enzyme-linked immunosorbent assays (ELISA) to track protein expression levels 
([Kim et al., 2008] and [Mok et al., 2010]). 
Pre-clinical studies on any delivery system will routinely involve pharmacokinetic, biodistribution and 
toxicity studies. Pharmacokinetics studies, following intravenous administration of naked siRNA versus 
formulated siRNA, facilitate the evaluation of parameters including half-life of siRNA, clearance, mean 
residence time and the volume of distribution and assess the influence of the delivery construct 
(formulation) on these parameters (Li et al., 2008c). Biodistribution studies are frequently performed using 
fluorescently labelled siRNA, for example FAM-siRNA. Visualisation in live animals or in isolated organs 
can be quantified using an optical imaging system ([Kim et al., 2008] and [Li et al., 2008c]). At the tissue 
level immunohistochemical staining of tumour sections and western blot analysis are frequently used to 
monitor the biological activities of siRNA. To ensure that tumour regression is not related to the induction 
of an immune response pre-clinical evaluation of non-viral delivery constructs must include evaluation of 
cytokine levels in untreated versus treated animals. A variety of cytokines including IL6, IL 12, TNF and 
IFN alpha have been evaluated following exposure over different time periods ([Li et al., 2008a] and [Li et 
al., 2008c]). Monitoring body weight during treatment and analysis of liver enzymes (i.e. alkaline 
phosphatase (AP) and gammaglutamyl transferase (GGT)) are also simple and effective methods of 
highlighting possible toxic effects (Hobel et al., 2010). 
 
6. Recent advances in the design of non-viral siRNA delivery vectors – potential for cancer 
therapeutics 
The progress over the past decade with gene transfer to mammalian cells has encouraged researchers to 
investigate the possibility of treating human diseases by gene-based therapies. However, despite substantial 
advances, the key challenge of delivery must be addressed before gene therapy can be safely and 
effectively applied in the clinic.  
In the past viral vectors dominated clinical trials in gene therapy due mainly to highly efficient gene 
transfer ([Hunt and Vorburger, 2002] and [Thomas et al., 2003]). However, safety issues including 
unwanted immune stimulation have limited their application in repeated administration schedules. In 
addition, the potential for mutagenesis may also have unexpected consequences in the host ([Thomas et al., 
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2003] and [Castanotto and Rossi, 2009]). Consequently, the number of viral vector trials has been steadily 
dropping over the last decade (Edelstein et al., 2007).  
In contrast, increasing attention has been focused on non-viral approaches for gene therapy as they have the 
potential to overcome many of the inherent disadvantages of viral vectors such as safety, immunogenicity, 
low transgene scale and high cost. Although numerous materials have been investigated as potential 
vehicles, in the past the development of synthetic vectors for gene delivery has been limited by low gene 
transfer efficiency, toxicity and in vivo instability ([Lv et al., 2006] and [Sanvicens and Marco, 2008]). 
Recently however, a range of new materials with improved safety and efficacy profiles have emerged 
facilitating the fabrication of targeted nanoparticles for specific delivery. These materials offer exciting 
opportunities for siRNA delivery in cancer therapy and are reviewed below. ([Green et al., 2008] and 
[Mintzer and Simanek, 2009]).  
6.1 Lipids and liposomes 
Traditionally these vectors are composed of a positive head group attached by a linker to a lipid 
hydrophobic moiety that may form amphiphilic liposomes. The cationic head group is functional for the 
binding of siRNA phosphate groups, and the lipid moiety is used as a fusogenic group to enhance 
penetration into the cells (Li and Szoka, 2007). The evolution of lipid-based vectors including their 
formulation strategies, cytotoxicity, transfection efficacy, extracellular uptake and intracellular trafficking, 
have been extensively reviewed ([Li and Szoka, 2007], [Tseng et al., 2009], [Liu and Huang, 2010] and 
[Schroeder et al., 2010]).  
More recently new approaches to lipid-like vectors have been reported for siRNA delivery ([Akinc et al., 
2008], [Yagi et al., 2009], [Semple et al., 2010] and [Tao et al., 2010]). For example, a new class of 
structurally diverse lipid-like delivery molecules termed ‘lipidoids’ were synthesised, using a one step 
synthetic strategy, by the conjugate addition of amines to an acrylate or acrylamide. Depending on the 
number of addition sites in the amino monomer, lipidoids were produced with between 1-17 tails (Akinc et 
al., 2008). These materials have demonstrated safe and effective gene silencing in mouse, rat and 
nonhuman primate models following local and systemic administration (Akinc et al., 2008). Using the 
ionisable cationic lipid, 1, 2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA) as a benchmark, Semple 
et al., (2010) used the proposed in vivo mechanism for endosomal release utilised by ionisable cationic 
lipids to guide the design of lipid vectors with superior delivery capacity. These novel lipids maintained a 
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neutral or low cationic surface charge at pH 7.4 and interacted with phospholipids in the endosomal 
membrane at low pH, thereby providing a better blood circulation, a reduced non-specific disruption of 
plasma membranes and an efficient endosomal escape. The optimum lipid identified, Dlin-KC2-DMA, was 
formulated as stable nucleic acid lipid particles (SNALP) using a controlled step-wise dilution method and 
achieved in vivo performance at siRNA doses as low as 0.01mg/kg in mice and 0.1mg/kg in nonhuman 
primates (Semple et al., 2010). Targeted versions of these lipids using both an endogenous ligand, 
apolipoprotein E (apoE) and an exogenous ligand, a multivalent N-acetylgalactosamine (GalNAc)-cluster, 
have proven to be highly effective for siRNA delivery to the liver (Akinc et al., 2010). This lipid-based 
technology is undergoing commercial development by Tekmira and Alnylam Pharmaceuticals. 
A set of lipid nanoparticles including cationic lipids, PEG and cholesterol have recently been investigated 
for their activities in delivering luciferase siRNAs to a liver-luciferase mouse model via systemic 
administration, in which a single dose of 3mg/kg siRNA formulated with the optimised lipid vector caused 
90% reduction of luciferase expression in liver and this target suppression lasted for at least 10 days (Tao et 
al., 2010). Lopez-Berestein and Sood have developed neutral nanoliposomal (dioleoyl-phosphatidylcholine, 
DOPC-based) vectors for siRNA-therapeutics in the treatment of ovarian cancer (Section 7) and this 
formulation is due to enter a Phase I clinical trial in solid tumours (Ozpolat et al., 2010).  
6.2 Polymeric nanoparticles 
Like cationic lipids/liposomes, cationic polymers also self-assemble with oppositely charged siRNA to 
form polyplexes (complexation of cationic polymers and siRNA). Polylysine (ε-poly-L-lysine) (PLL) is a 
small polypeptide of the essential amino acid L-lysine and was one of the first cationic polymers to be 
employed in gene-transfer research (Wanger et al., 1998). However, the relatively low efficiency of PLL, 
due to the chemical structure and the subsequent lack of buffering capacity resulting in poor escape from 
the endosome/lysosome, limit its clinical application (Mintzer and Simanek, 2009).  
Recently, a variety of novel PLL derivatives have been synthesised and investigated in an effort to decrease 
cytotoxicity, improve release of nucleic acids following endocytosis and achieve effective siRNA delivery 
([Inoue et al., 2008], [Meyer et al., 2009], [Watanabe et al., 2009], [Kano et al., 2009] and [Zhang et al., 
2010]). Meyer et al. have recently reported a siRNA delivery system using PEGylated PLL grafted to a 
pH-sensitive endosomolytic peptide and this siRNA-polymer conjugate produced effective 
endosome/lysosome escape due to the cleavage of the peptide at acid pH, however, the construct exhibited 
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considerable cytotoxicity (Meyer et al., 2009). In another study, the masking effects of PEG on PLL in vivo 
and the structural implications for biodistribution and tumoural accumulation were investigated, the 
optimised PEG-PLL from a series extended the half-life of siRNA and achieved high accumulation in 
tumour tissues without loss of the ability to associate with siRNA (Kano et al., 2009).  
Polyethylenimine (PEI), one of the most widely studied cationic polymers for gene-transfer, can be 
synthesised in different lengths (or molecular weights), be linear or branched and be substituted with 
various functionalised groups ([Green et al., 2008] and [Mintzer and Simanek, 2009]). The advantage of 
using PEI compared to PLL is the high transfection efficiency due to the buffering capability at the low pH 
of the lysosome inducing the ‘proton sponge effect’ (Mintzer and Simanek, 2009). However, it has been 
reported that PEI which escapes the endosome/lysosome can enter the nucleus where it may potentially 
disrupt endogenous gene expression (Godbey et al., 1999). Many initial studies have addressed the 
limitations of PEI including stability, cytotoxicity, intracellular trafficking and transfection efficiency 
([Jere et al, 2009], [Mintzer and Simanek, 2009] and [Beyerle et al., 2010]). Recently, novel biodegradable 
PEI derivatives for siRNA delivery have been designed to increase hydrophility, reduce cytotoxity, and 
enhance transfection efficacy using substitution of degradable moieties and copolymers ([Meyer et al., 
2008], [Zintchenko, et al., 2008], [Tietze et al., 2008], [Philipp et al., 2009] and [Park et al., 2010]). For 
instance, beta-propionamide-cross-linked oligoethyleneimine with a transferrin targeting ligand has been 
shown to successfully deliver siRNA by intravenous administration, and three treatments of the 
polymer/siRNA complex resulted in more than 80% reduction in target protein expression levels (Tietze et 
al., 2008). In addition, a newly developed siRNA vector comprising PEI grafted to hyaluronic acid (HA) 
via a disulfide linkage (PEI-SS-HA) was described and this non-toxic vector enhanced the serum stability 
of siRNA, facilitated specific cellular uptake by the HA receptor through endocytosis, and more 
importantly intratumoural injection of this complex significantly suppressed tumour development with 
decreased VEGF mRNA and protein expressions (Park et al., 2010).  
Poly (lactic-co-glycolic acid) (PLGA), a biodegradable and biocompatible copolymer, has been (FDA) 
(Food and Drug Administration)-approved for a variety of clincal applications and has been used in 
humans for several decades (Mundargi et al., 2008). Inhibition of tumor growth was reported after 
intratumoural injection of PLGA microspheres (35-45 μm) encapsulating PEI.siRNA nanoparticles targeted 
against VEGF, in which the anti-VEGF siRNA was first released extracellularly as a polyplex before being 
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internalised by cells (Murata et al., 2008). Recently, Saltzman and colleagues developed an intravaginal 
formulation for siRNA using PLGA nanoparticles (100-300 nm) which contained a ‘siRNA.spermidine’ 
core and led to sustained siRNA release based on pH sensitivity (Woodrow et al., 2009). Following 
administration of a single dose of complexed siRNA (0.1mg/kg) into the female mouse reproductive tract, 
efficient gene silencing was observed in the vaginal lumen and in the uterine horns for up to 14 days, with 
less irritation and inflammation compared to lipoplexes. 
Recently two interesting polymeric vectors following oral administration as a alternative non-parenteral 
route of administration for siRNA delivery have been published. In one case, particles using 
beta1,3-D-glucan (GeRPs), purified from baker’s yeast, were engineered to encapsulate siRNA and 
targeted to macrophages by means of the dectin-1 receptor (a major beta-glucan receptor) (Aouadi et al., 
2009). Oral gavage of mice with GeRPs containing siRNA directed against tumour necrosis factor alpha 
(TNF-alpha) depleted its mRNA in macrophages recovered from the peritoneum, spleen, liver and lungs, 
and lowered TNF-alpha levels. In addition silencing of Map4k4 was achieved which resulted in 
suppressing systemic inflammation. 
More recently, thioketal nanoparticles (TKNs) have been used to deliver siRNA to sites of intestinal 
inflammation (Wilson et al., 2010). TKNs are formulated from a polymer, poly-(1,4-phenyleneacetone 
dimethylene thioketal), that degrades selectively in response to reactive oxygen species (ROS). Therefore, 
when delivered orally, TKNs release siRNA in response to the abnormally high levels of ROS specific to 
sites of intestinal inflammation. Using a murine model of ulcerative colitis, it was shown that the TNK 
loaded with siRNA against the proinflammatory cytokine tumour necrosis factor-alpha (TNF-alpha) 
diminished TNF-alpha mRNA levels in the colon and protected the mice from ulcerative colitis. These 
orally active technologies offer the possibility to attenuate inflammatory responses in disease states and 
consequently may be exploited in oral delivery of siRNA for cancer immunology. 
6.3 Cyclodextrins 
Cyclodextrins (CDs) are a group of cyclic polysaccharides forming torus-like macrocycles, in which the 
internal cavity is hydrophobic and the external surface is hydrophilic (Mintzer and Simanek, 2009). CDs 
are categorised by the number of glucopyranose units in the ring, in which α, β, and γ-CD have 6, 7 and 8 
units respectively. Since these biocompatible cyclic oligosaccharides do not elicit immune responses and 
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have low toxicities in animals and humans, incorporating cyclodextrin into cationic polymers has 
demonstrated significant potential for efficient non-viral gene delivery ([Hu-Lieskovan et al., 2005], 
[Heidel et al., 2007], [Bartlett and Davis, 2008], [Davis et al., 2010] and [Mellet et al., 2010]). Davis and 
co-workers have shown that incorporation of β-CD monomers (AA) into polycations (BB) with an order 
like -AA-BB-AA-BB-, using the polycations as a spacer, bound nucleic acids ([Hu-Lieskovan et al., 2005], 
[Heidel et al., 2007] and [Bartlett and Davis, 2008]). The structure-activity relationship of 
beta-cyclodextrin-based polycations demonstrated that improvement of the hydrophilicity of the spacer unit 
could reduce cytotoxicity, probably resulting from increased hydration around the CD monomers and 
higher flexibility. However, initial data indicated that β-CD-based polyplexes did not exhibit buffering 
capacity in the endosomal environment unless further modified by an imidazole-distal moiety (Kulkarni et 
al., 2005). In order to avoid aggregation in vivo, as seen with other cationic systems, a PEG group attached 
via adamantane (a hydrophobic molecule) was incorporated into the beta-CD-containing polycations 
through the formation of an inclusion complex. Further modification of the beta-CD polycations with 
adamantane-PEG-transferrin has been shown to be effective in cell-targeted siRNA delivery in three 
melanoma patients (Davis et al., 2010). 
 
An alternative strategy using cyclodextrins as potential core molecules which can be modified directly with 
various functional groups including: polycations, lipophilic chains (amphiphilic vectors), PEG chains and 
targeting ligands to create a library of CD vectors has also been reported ([Sallas and Darcy, 2008], [Cryan 
et al., 2004a], [Cryan et al., 2004b] and [McMahon et al., 2008]). Amphiphilic cyclodextrins have been 
shown to form vesicles with the potential to encapsulate nucleic acids inside the aqueous core ([Donohue et 
al., 2002], [Sallas and Darcy, 2008] and [O’Driscoll, 2008]). There are many advantages associated with 
this approach, CDs, as oligosaccharides, have low immunogenicity and the availability of multiple sites for 
attachment of functional groups confers flexibility to accommodate the targeting requirements for a range 
of therapeutic applications.  
6.4 Cell penetrating peptides 
Since the first discovery, in 1988, that the exogenous addition of the full-length HIV-1 TAT protein to cells 
resulted in increased cell membrane penetration, protein transduction domains (PTDs), also known as 
cell-penetration peptides (CPPs)) comprising short amino acid sequences have been shown to complex 
nucleic acids into nanoparticles and interact with the plasma membrane in a receptor-independent manner 
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resulting in efficient cellular uptake ([Deshayes et al., 2008], [Fonseca et al., 2009], [Eguchi and Dowdy, 
2009] and [Sawant and Torchilin, 2010]). The increasing application of these novel vectors to siRNA 
delivery demonstrates that PTDs have great potential in the design of delivery constructs for siRNA 
therapeutics. The major PTDs studied include; penetratin, transportan, TAT, amphipathic peptide and 
poly-arginine ([Fonseca et al., 2009], [Mathupala, 2009] and [Eguchi and Dowdy, 2009]). 
Initial studies utilised electrostatic interactions between the cationic CPPs and the negatively charged 
siRNA to form NPs. Divita et al. demonstrated that a secondary amphipathic CPP achieved stable 
complexes with siRNA and led to enhanced transfection into a wide variety of cell lines and delivery of 
siRNA mediated by this novel CPP, using low concentrations, achieved significant knockdown of of the 
target gene, without showing significant cytotoxicity (Crombez et al., 2009a). The development of MPG-8 
(an improved variant of CPPs) formed nanoparticles with siRNAs and promoted their efficient delivery 
into primary cell lines (Crombez et al., 2009b). Formulation of siRNA with this novel CPP significantly 
improved tissue distribution and stability of siRNA in vivo; this formulation containing siRNA against 
Cyclin B1 also efficiently down-regulated the targeted mRNA and protein expression and inhibited tumour 
growth following intratumoural injection in a prostate xenograft mouse model (Crombez et al., 2009b).  
Subsequently, the covalent attachment of CPPs to siRNAs to achieve a soluble, monomeric siRNA was 
investigated. However, the ease with which cationic peptides bind to and condense siRNA makes this 
strategy difficult to regulate ([Deshayes et al., 2008] and [Eguchi and Dowdy, 2009]). Furthermore, the 
covalent bond that links the CPPs to the siRNA molecules must be reversible inside the cellular 
environment, taking into account the nuclear localisation properties of CPPs and the cytoplasmic 
localisation of the RNAi pathway ([Fonseca et al., 2009], [Endoh and Ohtsuki, 2009] and [Eguchi and 
Dowdy, 2009]). Consequently, an optimal chemical conjugation (i.e. disulfide bond) is required to free 
siRNAs upon exposure to the reducing cytoplasm environment.  
Engineered non-viral vectors comprising lipids/polymers and CPPs with structural features mimicking 
those of viral vectors have shown potential for siRNA delivery ([Hatakeyama et al., 2009], [Xiong et al., 
2010] and [Akita et al., 2010]). A multifunctional envelope-type nano device (MEND) grafted by 
octaarginine (R8) peptides successfully silenced the suppressor of cytokine signalling 1 (SOCS 1, a 
negative-feedback regulator of the immune response in bone marrow-derived dendritic cells (BMDCs). 
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This approach was used for ex vivo siRNA delivery to dendritic cells in the development of cancer vaccines 
[Akita et al., 2010]).  
6.5 Inorganic materials 
Gold nanoparticles (GNPs) have been extensively studied in biological and photothermal therapeutic fields 
and the utilisations of GNPs as ‘inorganic nanomedicines’ along with their basic physical, chemical and 
optical properties have previously been described ([Ghosh et al., 2008], [Lee et al., 2009], [Boisselier and 
Astruc, 2009] and [Chanda et al., 2010]). The combination of pharmaceutical products with gold 
nanoparticles has been stimulated by the capability of the gold nanoparticles to conjugate a wide range of 
organic molecules, their low cytotoxicity and strong and tunable optical absorption. Gold nanoparticles can 
be directly conjugated with drug molecules and siRNA, via ionic or covalent bonding, or by physical 
adsorption, resulting in a possible way to improve therapeutic efficacy ([Ghosh et al., 2008] and [Boisselier 
and Astruc, 2009]). 
In the case of siRNA delivery, the ability for surface modification of GNPs with functional moieties is an 
added bonus. Polymer-modified gold nanoparticles have been reported to improve biocompatibility and 
hydrophilicity. When the original capping ligands on some GNPs (i.e. gold nanorods) that caused 
cytotoxicity were replaced with PEG, significantly improved cell viability was achieved (Boisselier and 
Astruc, 2009). The use of a polymer such as PEG also facilitates conjugation of targeting ligands for 
specific delivery, preventing aggregation of the GNPs in bodily environments and ensuring a longer 
circulation of the particles following in vivo administration ([Choi et al., 2010] and [Lu et al., 2010]). Lee 
et al. developed a novel GNP-based siRNA delivery system using amine-functionalised GNPs. In this case, 
stable polyelectrolyte complexes were formed through electrostatic interactions with negatively charged 
siRNA-PEG conjugates which have a di-sulfide linkage, cleavable under reductive cytoplasm condition 
(Lee et al., 2008). The resultant core/shell type polyelectrolyte formulation surrounded by a PEG layer had 
a well-dispersed nanostructure, protecting these complexes against uncontrollable aggregation. These 
siRNA/gold particles significantly blocked the expression of a target gene within the PC-3 human prostate 
cancer cells without showing severe cytotoxicity (Lee et al., 2008). Another promising siRNA delivery 
vector was described by Braun et al., using GNPs modified with siRNA-PEG via a laser sensitive linker 
(Braun et al., 2009). The pulsed near-infrared (NIR)-induced release of siRNA through the cleavage of the 
linker from the complexes was found to be power- and time-dependent, although the escape of siRNA from 
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endosomes occurred above a critical pulse energy attributed to local heating and cavitation (Braun et al., 
2009).  
Single-walled carbon nanotubes (SWNT) and multi-walled carbon nanotubes (MWNT) were first 
discovered in the late 1950s and these materials have recently provided great promise for gene therapies 
following functionalisation techniques. Oxidised SWNT and MWNT can be modified at their carboxylic 
groups with proteins, nucleic acids, oligonuceotides, sugar moieties, polyoxide derivatives, etc. ([Mintzer 
and Simanek, 2009] and [Liu et al., 2009a]). A variety of studies have investigated carbon nanotubes for 
siRNA delivery ([Herrero et al., 2009], [Podesta et al., 2009], [Liu et al., 2009b] and [McCarroll et al., 
2010]). Yang et al. used cationic SWNT to successfully deliver siRNA against CD80 (a costimulatory 
protein expressed by antigen-presenting cells to activate T-cells) by i.v. administration, leading to 
significant inactivation of CD8 expression in a Lewis lung carcinoma bearing animal model (Yang et al., 
2006). Subsequently, a newly developed SWNT was described to efficiently complex siRNA and this 
formulation carrying anti-hTERT siRNA significantly suppressed tumour growth in a tumour bearing 
mouse model following intralesional injection, combined with reductions in targeted mRNA and protein 
(Zhang et al., 2006). Amino-functionalised multi-walled carbon nanotubes (MWCNT) carrying siRNA 
were used to treat a human lung carcinoma model in vivo and the results indicated that the 
MWCNT–siRNA complexes administered intratumorally elicited delayed tumour growth and increased 
survival of the xenograft animals (Podesta et al., 2009). 
6.6 Photochemical internalisation 
With most gene delivery vectors, the therapeutic gene is taken into the cell by endocytosis and for many 
vectors an efficient mechanism for translocating the gene out of the endocytic vesicles is a major barrier to 
realisation of the therapeutic potential. Photochemical internalisation (PCI) is a light-triggered method that 
employs amphiphilic photosensitisers to destabilise endosomal vesicles, thereby releasing endocytosed 
particles at their site of action before being degraded in lysosomes. Recently, it has been studied as a 
delivery technology when combined with non-viral vehicles for both reporter and therapeutic genes ([Berg 
et al., 2007], [Oliveira et al., 2007], [Oliveira et al., 2008] and [Raemdonck et al., 2010]). For instance, it 
has recently been reported that application of PCI at a later time-point post-transfection significantly 
increased the target gene knockdown when siRNA was delivered by cationic dextran nanogels 
(Raemdonck et al., 2010). 
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7. Delivery of siRNA in cancer therapy 
A variety of non-viral vectors have been used for targeted delivery of siRNA in the treatment of a wide 
range of different cancer types, with varying degress of success. In vivo studies are summarised in Table 1 
according to the delivery vector type, cancer type, target gene, route of administration, experimental animal 
model and endpoint comments. Recent studies using the non-viral approach for cancer therapy are 
reviewed below. 
Table 1. 
An improved understanding of the biochemical characterisation of tumour antigens and the identification 
of the cellular and molecular mechanisms resulting in activation of innate and adaptive immune cells has 
been of paramount importance in the development of tumour immunology ([Grivennikov et al., 2010] and 
[Zwirner et al., 2010]). This work has stimulated studies on how to modulate immune responses to treat 
tumours. For instance, Alshamsan et al. described a unique nanoparticle based on PEI modified with stearic 
acid (StA) to deliver siRNA for efficient downregulation of STAT3 (signal transducer and activator of 
transcription 3, an immune suppressor gene) (Alshamsan et al., 2010). Compared to unmodified PEI 
complexes, the formulation produced a significant decrease in tumour growth after siRNA/PEI-StA local 
treatment in a B16F10 melanoma bearing mouse model, accompanied with significant increases in the 
levels of in IL-6 and Caspase 3 (an indicator of apoptotic activity) and marked decreases in the levels of 
VEGF and STAT3 in the tumour tissue (Alshamsan et al., 2010).  
Huang and associates developed a formulation for successful systemic delivery of siRNA to treat lung 
metastatic tumours ([Li et al., 2008a] and [Li et al., 2008b]). In this system, the nucleic acids (siRNAs and 
carrier DNA), a polycationic peptide (protamine) and a cationic liposome are initially prepared in a 
condensed core. The resulting core is then modified by a PEG-lipid containing the tumour targeting ligand, 
anisamide, that specifically recognises sigma receptors overexpressed on many carcinomas ([Li et al., 
2008a] and [Li et al., 2008b]). In a mouse model of lung metastasis, siRNAs against the cancer associated 
genes MDM2 (an inactivator for p53), c-myc (transcription factor that promotes cell proliferation) and 
VEGF co-formulated in a targeted system administered intravenously caused simultaneous silencing of 
each of the genes, resulting in prolonged survival of animals with little local and systemic immunotoxicity 
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(Li et al., 2008a). This formulation has recently been further developed to incorporate a lipid coated 
biodegradable calcium phosphate nanoparticle, with improved immunotoxicity (Li et al., 2010b). 
Since hepatitis B and C viruses (HBV & HCV) are high risk factors for liver cancer, they offer good targets 
for siRNA based therapeutics An anti-HBV formulation was generated by condensation of siRNA with 
cationic liposomes to form core particles, into which an aminoxy cholesteryl lipid was incorporated (via an 
acid sensitive linker) for convenient surface postcoupling with PEG to achieve pH-triggered PEGylated 
siRNA-nanoparticles (Carmona et al., 2009). This formulation resulted in suppression of the target gene by 
up to 3-fold relative to controls over 28 days following hydrodynamic administration in a replicating HBV 
bearing mouse model. 
Sood and co-workers reported a novel system using mesoporous silicon particles loaded with neutral 
nanoliposomes containing siRNA against the EphA2 oncoprotein (overexpressed in most cancers, 
including ovarian cancer) (Tanaka et al., 2010). A single i.v. administration of these particles in 
tumour-bearing mouse models substantially reduced tumour size, angiogenesis and cell proliferation 
compared with the control group, with no significant changes in serum chemistries or in proinflammatory 
cytokines. Recently, chitosan nanoparticles conjugated with an Arg-Gly-Asp (RGD) peptide specifically 
targeting the integrin overexpressed in ovarian cancer has been utilised for effective siRNA delivery (Han 
et al., 2010). Intratumoural injection of these particles containing siRNAs targeting multiple growth 
promoting genes (POSTN, FAK, and PLXDC1) successfully suppressed the tumour growth in animal 
models grafted by ovarian cancers. 
Infection with HPV (human papillomavirus, i.e. HPV E6 and HPV E7) is a major risk factor for cervical 
cancer. Liu et al. intratumourally delivered anti-E6 and -E7 siRNA using Oligofectamine™ (Invitrogen) 
combined with paclitaxel to SiHa cervical ovarian tumours subcutaneously grafted on nude mice, leading 
to reduction of the tumour size compared to siRNA alone (Liu et al., 2009c). A novel lipid particle using a 
hydration-of-freeze-dried-matrix (HFDM) method to encapsulate siRNA has recently demonstrated 
remarkable serum stability and efficiently targeted E6/7 oncogenes in cervical tumour following i.v. 
injection, resulting in a reduction of tumour size accompanied with silencing of the target gene expression 
(Wu et al., 2010).  
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In the case of prostate cancer, siRNAs complexed with aptamers (oligonucleic acid or peptide molecules) 
were capable of specifically targeting PSMA (a prostate cancer cell membrane receptor), and silencing two 
survival genes PLK1 (polo-like kinase 1) and BCL2 (B-cell lymphoma 2) in a xenograft mouse bearing 
prostate carcinoma (McNamara et al., 2006). Addition of a PEG moiety to these aptamer-siRNA chimeras 
significantly reduced the PSMA-expressing tumours in athymic mice after systemic administration, mainly 
due to the enhanced circulating half-life from <35min to >30hour (Dassie et al., 2009). 
The interaction between PEG-conjugated anti-VEGF siRNA (siRNA-PEG) and PEI was described by Park 
and associates (Kim et al., 2008), this involved spontaneous formation of nanoscale polyelectrolyte 
complex micelles, incorporating a siRNA/PEI inner core with a surrounding PEG shielding layer. 
Intravenous as well as intratumoural administration of this formulation effectively inhibited VEGF mRNA 
and protein expression at the tumour tissue and inactivated tumour growth in a mouse xenograft model 
with prostate carcinoma. 
The expression of CK2 and its subunits has effects on NF-kappaB-mediated and TP53-mediated signal 
activation and gene expression, the malignant phenotype and chemosensitivity in head and neck squamous 
cell carcinoma (HNSCC). siRNA against CK2 subunits was encapsulated inside tenfibgen nanocapsules 
and administered by intratumoural injection into a HNSCC xenograft animal model, resulting in 
suppression of tumour size accompanied with modulation of CK2 and NF-kappaB regulated molecules and 
induction of apoptosis (Brown et al., 2010).  
 
8. Future prospects 
Tekmira Pharmaceuticals Corporation initiated a Phase I human clinical trial (TKM-PLK1) in December 
2010 to establish safety and identify the maximum tolerated dose in relapsed or refractory cancer patients 
(www.tekmirapharm.com). TKM-PLK1, a lipid nanoparticle based siRNA therapeutic against PLK1 
(polo-like kinase 1), has the potential to provide both direct tumour cell killing and sensitisation of tumour 
cells to the effects of chemotherapy drugs (www.tekmirapharm.com). In addition, Alnylam 
Pharmaceuticals, Inc. announced preliminary clinical data from its ongoing Phase I trial with ALN-VSP (a 
siRNA therapeutic formulated in SNALP developed by Tekmira Pharmaceuticals Corporation) for the 
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treatment of advanced solid tumors (www.alnylam.com). The study has not yet reached a maximum 
tolerated dose and is continuing enrollment with dose escalation. 
Another Phase I clinical trial (Atu027) has been announced by Silence Therapeutics to treat a broad range 
of solid tumours including gastrointestinal (including pancreatic), non-small cell lung, prostate, melanoma, 
liver and others (www.silence-therapeutics.com). Atu027, a chemically modified siRNA formulated in 
lipsosomes against PKN3 (protein kinase N3), may result in a reduction in nutrient and oxygen supply to 
solid tumours, as well as interfering with tumour formation, endothelial cell motility and metastasis (Santel 
et al., 2011).  
A promising clinical trial currently underway using a non-viral vector with a targeting ligand is the 
RONDEL
TM
 (RNAi/Oligonucleotide Nanoparticle Delivery) technology developed by Calando 
Pharmaceuticals. This novel cyclodextrin-based system containing anti-RRM2 (M2 subunit of 
ribonuceotide reductase) siRNA (commercially termed CALAA-01), has reached phase I clinical trials in 
the treatment of solid tumours. Following intravenous administration to patients, no significant drug-related 
toxicities have been detected (Davis et al., 2010). It was announced recently that in addition to CALAA-01, 
pre-clinical development of a second siRNA oncology therapeutic is underway 
(www.calandopharma.com). CALAA-02 uses the same delivery system as CALAA-01, but will target 
hypoxia inducible factor-2 (HIF-2), which is over-expressed in many solid tumours and has a role in 
tumourigenesis. These works provide proof of concept for non-viral targeted delivery of siRNA as a cancer 
therapeutic and illustrates the potential for further innovative delivery approaches. 
Although the progress of RNAi therapeutics has been remarkable compared to conventional cancer 
treatments within the last decade, many challenges remain. As the treatment of cancers commonly requires 
systemic delivery rather than more easily achievable local administration, significant opportunities exist to 
develop further the concept of targeted nanoparticulate non-viral delivery constructs which prolong the 
half-life of siRNA, are non-immunogenic and which achieve the required level of gene silencing at the 
disease site. 
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Figure 1. Identification of potential gene related targets for cancer therapy using 
siRNA-based therapeutics. (Adapted from Masiero et al., 2007) 
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Figure 2. Barriers to systemic siRNA delivery via blood circulation: Rapid renal filtration of 
naked siRNA due to size (<10nm) (1). Degradation by blood nucleases (2). Binding of siRNAs 
formulated with unmodified cationic vectors by negatively charged serum proteins (3), resulting in 
particle aggregation and opsonisation (4). Delivery strategies including siRNA complexation via 
shielding materials (i.e. PEG or neutral, small molecular weight lipids) with/without a targeting 
ligand can avoid aforementioned barriers (1, 2, 3 and 4) and prolong blood circulation.  
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Figure 3. Delivery strategies designed to exploit the physiological and biochemical environment 
of the tumour: Shielded siRNA formulations, with/without targeting ligand, of optimum size to 
penetrate through the leaky endothelium into the tumour via the EPR effect (1). Targeted 
constructs utilise specific tumour receptors to enhance specific cellular uptake (2), detachment of 
shielding materials in the tumour extracellular fluid (cleavage of hydrophilic PEG chains may 
occur by cleavage of pH or enzyme sensitive linkers) to facilitate cellular uptake (3 and 4), 
followed by escape from or avoidance of the endosome/lysosome (5) disassociation from the 
vector (6) to interact with RISC. 
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Table 1. A summary of studies on the in vivo delivery of siRNA in cancer therapy, including: delivery vector, cancer type, target 
cancer-associated gene, route of administration and animal model. (i.t. = intratumoural, i.v. = intravenous, i.p. =intraperitoneal, CNS = central 
nervous system and S.C. = subcutaneous). 
 
Delivery vector Therapy/cancer type 
Target 
Cancer-associated 
gene 
Route of administration 
 
Animal model 
 
Endpoint comments References 
Lipid  
 Cationic cardiolipin 
analogue 
MDA-MB-231 human 
breast tumour 
C-raf Administered by i.v. 
S.C. xenograft mouse Tumour suppression 
and less toxicity 
Chien et al., 2005 
 Neutral Liposomes 
HeyA8 or SKOV3ip1 
tumour 
(Ovarian Cancer) 
β-2 adrenergic 
receptor 
Administered by i.p. 
Orthotopic 
xenograft mouse 
Behavioural stress can 
enhance tumour 
angiogenesis 
Thaker et al., 2006 
Lipids with apo A-I 
ligand 
HBV replication 
(Liver cancer) 
HBV Administered by i.v. HBV infected mouse 
Efficient anti-viral 
activity without toxicity 
Kim et al., 2007 
   Neutral Liposomes 
HeyA8 or SKOV3ip1 
tumour 
(Ovarian Cancer) 
IL-8  Administered by i.p. 
 
Orthotopic xenograft 
mice 
IL-8 is associated with 
poor clinical outcome 
in human ovarian 
carcinoma 
Merritt et al., 2008 
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  Cationic Lipoplexes 
Hep3B tumour 
(Liver Cancer) 
Rec QL1 DNA 
helicase 
Administered by i.t. and 
i.v. 
S.C. and metastasis 
xenograft mice 
Inactivation of cancer 
cell proliferation and no 
noticeable toxicity 
Futami et al., 2008 
PEGylated liposomes 
with anisamide ligand 
B16 tumour 
(Lung Metastasis) 
MDM2/c-myc/VE
GF 
Administered via i.v. 
Metastasis xenograft 
mouse 
Prolonged survivial of 
animals with little 
immunotoxicity 
Li et al., 2008a 
   Liposomes with 
Vitamin-A ligand 
Lethal liver cirrhosis 
(Liver cancer) 
gp46 Administered by i.v. 
Chemically induced 
mouse of liver cirrhosis Prolonged survival time 
Sato et al., 2008 
Neutral lipid bilayer and 
hydrophilic polymers 
Lung carcinoma and 
prostate cancer 
KLF5 Administered by i.v. S.C. xenograft mice 
Extended half-life of 
siRNA and effective 
gene knockdown 
Yagi et al., 2009 
 PEGylated liposomes 
with anisamide ligand 
H460 tumour 
(Lung Cancer) 
EGFR Administered by i.v. 
 
S.C. xenograft mouse 
An improved 
formulation achieving 
tumour suppression 
Chen et al., 2009 
PEGylated pH-sensitive 
liposomes 
HBV replication 
(Liver cancer) 
HBV 
Administered by 
hydrodynamic injection 
HBV infected mouse 
Compatible treatment 
efficacy observed from 
lamivudine 
Carmona et al., 2009 
 Mesoporous silicon 
particles and neutral 
Liposomes 
HeyA8 or SKOV3ip1 
tumours 
(Ovarian Cancer) 
EphA2 Administered by i.v. 
Orthotopic xenograft 
mouse 
Tumour blockage and 
no proinflammtory 
cytokines 
Tanaka et al., 2010 
Polymer  
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PEGylated 
cyclodextrin-polycation 
with transferrin ligand 
Metastatic Ewing’s 
sacrcoma 
EWS-FLI1 Administered by i.v. 
Metastasis xenograft 
mouse 
Slowing tumour growth 
without immunotoxicity 
Hu-Lieskovan et al., 
2005 
 PEI 
U87 glioblastoma 
（Brain cancer） 
PTN Administered into CNS 
Orthotopic xenograft 
mouse 
Antitumour effect 
without significant 
toxicity 
Grzelinski et al., 
2006 
Chitosan Breast cancer RhoA Administered by i.v. S.C. xenograft mouse 
Tumour inhibition and 
no toxicity 
Pille et al., 2006 
PEI and PLGA 
microshperes 
S-180 tumour 
(Sarcoma) 
VEGF Administered by i.t. S.C. xenograft mouse Tumour inhibition Murata et al., 2008 
 PEG-PCL/MA 
Hormone-dependent 
breast cancers 
ERα Administered by i.v. S.C. xenograft mouse Tumour inactivation Bouclier et al., 2008 
 PEGylated siRNA 
formulated with PEI 
Prostate carcinoma VEGF 
Administered by i.v. and 
i.t 
S.C. xenograft mouse Tumour suppression 
and no significant 
toxicity 
Kim et al., 2008 
 PEGylated 
cyclodextrin-polycation 
with transferrin ligand 
N2A tumour 
(Neuroblastoma) 
RRM2 Administered by i.v. 
S.C. xenograft mouse 
Mathematical model of 
siRNA-mediated gene 
silencing and tumour 
inhibition 
Bartlett and Davis, 
2008 
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 Dendriworm 
Glioblastoma 
(Brain cancer) 
EGFR 
Administered by 
convection-enhanced 
delivery 
Transgenic mouse 
model of glioblastoma 
Suppression of EGFR 
expression and well 
tolerated 
Agrawal et al., 2009 
 Oligofectamine™  
SiHa cervical ovarian 
tumour 
HPV E6 
HPV E7 
Administered by i.t.  S.C. xenograft mouse Tumour inhibition Liu et al., 2009c 
 PEI B16F10 lung metastasis WT1 
Administered by an 
aerosol system 
Metastasis xenograft 
mouse 
The decreased number 
and size of lung tumour 
foci and angiogenesis 
Zamora-Avila et al., 
2009 
 Tenfibgen nanocapsules 
Head and neck 
squamous cell 
carcinoma 
CK2 Administered by i.t. S.C. xenograft mouse 
Suppression of tumour 
with antitumour 
immunoresponse 
Brown et al., 2010 
Chitosan with RGD 
ligand 
SKOV3ip1, HeyA8, 
and A2780 tumours 
(Ovarian cancer) 
POSTN, FAK, and 
PLXDC1 
Administered by i.t. 
Orthotopic xenograft 
mouse 
Tumour suppression 
Han et al., 2010 
PEGylated GNPs with 
folate ligand 
Cervical cancer NF-kappaB Administered by i.v. 
S.C. xenograft mouse Tumour delay 
following apoptosis 
Lu et al., 2010 
 Soluble protrusion array 
device 
Skin disorders Reporter gene Microneedle array 
 
Transgenic reporter 
mouse  
 
Effective gene silencing 
Gonzalez-Gonzalez 
et al., 2010 
Others  
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CPP 
(Short argnine peptide) 
Ovarian carcinoma HER2 Administered by i.t. S.C. xenograft mouse 
Tumour suppression 
and no toxicity 
Kim et al., 2010 
Protamine with antibody 
HIV 
envelope-expressing 
B16 melanoma 
MDM2/c-myc/VE
GF 
Administered by i.t. and 
i.v. 
S.C. xenograft mouse Tumour suppression 
without toxicity 
Song et al., 2005 
Protamine with antibody 
K562 tumour 
(leukemia) 
Cyclin D1 Administered by i.v. 
Leukaemia xenograft 
mouse 
Potential targeting 
delivery in leukaemia 
Peer et al., 2007 
Atelocollagen Bone metastasis 
EZH2 
p110- 
Administered by i.v. 
Metastasis xenograft 
mouse 
Inhibition of metastatic 
tumor growth in bone 
tissues and no toxicity 
Takeshita et al., 2005 
Bacterially derived 
minicells with antibody 
Caco-2 colon tumour 
(Colon cancer) 
MDR-1 Administered by i.v. S.C. xenograft mouse 
Increased survival via 
enhanced drug 
sensitivity 
MacDiarmid et al., 
2009 
Conjugation with TLR9 
ligand 
B16 lung metastasis STAT3 Administered by i.v. 
Metastasis xenograft 
mouse 
Tumour inhibition 
through antitumour 
immune responses 
Kortylewski et al., 
2009 
PEGylated aptamer 
conjugation 
Prostate carcinoma PLK1 Administered by i.v. 
S.C. xenograft mouse Regression of tumour 
tissue without toxicity 
Dassie et al., 2009 
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